Mint Tower Capital Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Mint Tower Capital Management’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,000	Closed	-$3K	–	471
2020 Q4	$3K	Buy	+15,000	New	+$190K	﹤0.01%	254

Mint Tower Capital Management's PRVL Position: Q1 2021 in Review

Mint Tower Capital Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 15,000 shares — an estimated $3K sold.

Mint Tower Capital Management first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $3K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Mint Tower Capital Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Mint Tower Capital Management sold 15,000 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $3K.
Mint Tower Capital Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Mint Tower Capital Management's Prevail Therapeutics Inc. Common Stock position peaked at $3K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Mint Tower Capital Management's 13F filing for Q1 2021, filed 12 May 2021.